Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.75 |
| ▸ | CA2 | P00918 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 5/20 | 0.71 |
| ▸ | NAMPT | P43490 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27996234 | 0.94 | SMN1; SMN2 (0.73) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11256877 | 0.92 | MAPT (0.68) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11240039 | 0.90 | MAPT (0.73) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11255125 | 0.89 | MAPT (0.64) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL4051167 | 0.88 | MAPT (0.75) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11235432 | 0.88 | MAPT (0.75) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11246529 | 0.87 | CA1 (0.76) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL16585699 | 0.86 | CA1 (0.72) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL18415526 | 0.86 | CA1 (1.00) | CA1CA2SMN1; SMN2MAPTRAB9A | |
| SCHEMBL11247013 | 0.85 | MAPT (0.71) | CA1CA2SMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| WO-2010130638-A1 | SULFONAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-7384952-B2 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-10 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-100345853-C | Pyrazolopyrimidine compound and method for producing the same | TANABE SEIYAKU CO (JP) | 2007-10-31 | — | — | CN | disclosed |
| EP-1390340-A4 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-23 | — | — | US | disclosed |
| US-7115784-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-06-22 | — | — | US | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
| US-4362892-A | ARALKYLANILINES, ANTICHOLESTEROL AGENTS | BEECHAM GROUP LIMITED (GB) | 1982-12-07 | — | — | US | disclosed |
| US-4350822-A | Antilipidemicpara-[aryl(alkyl or alkenyl)amino]benzoic acid derivatives | AMERICAN CYANAMID COMPANY (US) | 1982-09-21 | — | — | US | disclosed |
| US-4246275-A | Antilipidemic para-[thienyl and furyl (alkyl or alkenyl)amino]-benzoic acid derivatives | AMERICAN CYANAMID COMPANY (US) | 1981-01-20 | — | — | US | disclosed |
| US-4206145-A | ALKANOYL-SUBSTITUTED ARALKYLAMINES | BEECHAM GROUP LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| US-4185115-A | Antilipidemic para-[aryl(alkyl or alkenyl)amino]-benzoic acid derivatives | AMERICAN CYANAMID COMPANY (US) | 1980-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264673-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CA1 144/4885CA2 212/4885SMN1; SMN2 3768/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CA1 144/4885CA2 212/4885SMN1; SMN2 3768/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | CA1 144/4885CA2 212/4885SMN1; SMN2 3768/4885 |
| US-20060135525-A1 | Pyrazolopyrimidine compound and a process for preparing the same | KCNJ2, KCNN2, KCNH2 | CA1 3575/4885CA2 533/4885SMN1; SMN2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.